Four line graphs show biomarker concentrations over time. Graphs A and B plot pTau@181 levels for psychosis and behavioral impairment groups. C and D show NfL levels, similarly divided. Each graph displays 'Baseline,' 'Incident,' and 'None' categories.
Elevated plasma #pTau181 and #NfL levels in #AlzheimerDisease patients largely reflect broad neuropsychiatric impairment rather than psychosis alone. ja.ma/4sq0bW6
Four graphs display longitudinal trajectories of plasma biomarker concentrations within psychosis and behavioral impairment groups, plotting concentrations of pTau@181 and NfL over time for baseline, incident, and none groups.
Elevated plasma #pTau181 and #NfL levels in #AlzheimerDisease patients largely reflect broad neuropsychiatric impairment rather than psychosis alone. ja.ma/4rvSTQf
【Labcorp、ロシュ開発のアルツハイマー除外用血液検査「Elecsys pTau181」を全米展開】
FDA承認の高精度血液検査が、認知症初期診断を革新。
✔ 陰性的中率97.9％でアルツハイマー病を除外
✔ PET・腰椎穿刺を伴わない非侵襲的検査
✔ プライマリケアで利用可能、全国2,200拠点へ拡大
認知症の早期鑑別と医療アクセスの平準化へ。
“除外診断”が、早期介入の新たな第一歩となる。
#Labcorp #RocheDiagnostics #Elecsys #pTau181 #アルツハイマー病 #認知症 #神経内科 #血液バイオマーカー
Labcorp Set to Provide First FDA-Cleared Alzheimer's Blood Test in Primary Care by 2026 #USA #Burlington #Labcorp #Alzheimer's_Test #pTau181
Spotlight on Alzheimer’s: The biomarker race
#sensitiveandspecific #diagnostics #diagnostictesting #screening #alzheimers #alzheimersassociation #cognitivedecline #biomarkers #pTau #liquidbiopsy #pTau217 #pTau181
